12:00 AM
 | 
May 31, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Clobazam: Phase III data

Top-line data from a double-blind, international Phase III trial in 238 patients showed that the 2 highest doses of clobazam met the primary endpoint of significantly reducing the average number of drop seizures per week from the 4-week baseline period to the 12-week...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >